TickerFacts.

Monte Rosa Therapeutics, Inc. (GLUE): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$22.80M
Year ended 2025-12-31
-$24.07M
Trailing 12 months to 2026-06-30
$42.00M2020-12-31: -$23.05M2021-12-31: -$59.36M2022-12-31: -$92.47M2023-12-31: -$43.80M2024-12-31: $42.00M2025-12-31: -$22.80M-$22.80M
2020-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$22.80Mn/m2026-03-17, From 2025-01-01
2024-12-31$42.00Mn/m2026-03-17, From 2024-01-01
2023-12-31-$43.80Mn/m2025-03-20, From 2023-01-01
2022-12-31-$92.47Mn/m2024-03-14, From 2022-01-01
2021-12-31-$59.36Mn/m2023-03-16, From 2021-01-01
2020-12-31-$23.05Mn/a2022-03-29, From 2020-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31-$22.80Mn/m
Atara Biotherapeutics, Inc. (ATRA)2025-12-31-$50.94Mn/m
Agenus Inc (AGEN)2025-12-31-$77.19Mn/m
ImmunityBio, Inc. (IBRX)2025-12-31-$304.94Mn/m
Beam Therapeutics Inc. (BEAM)2025-12-31-$345.10Mn/m
Century Therapeutics, Inc. (IPSC)2025-12-31-$103.88Mn/m
Sutro Biopharma, Inc. (STRO)2025-12-31-$177.23Mn/m
Ginkgo Bioworks Holdings, Inc. (DNA)2025-12-31-$171.06Mn/m
REGENXBIO Inc. (RGNX)2025-12-31-$123.96Mn/m

Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗